Ophthalmic Formulations of Squalamine

Number of patents in Portfolio can not be more than 2000

United States of America Patent

APP PUB NO 20130281420A1
SERIAL NO

13817306

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention relates to ophthalmic formulations of squalamine or its pharmaceutically acceptable salts for the treatment of conditions of the eye such as, for example, wet age-related macular degeneration (wet AMD), choroidal neovascularization, retinopathy, dry age-related macular degeneration (dry AMD), polypoidal choroidal vasculopathy, neovascularization following ocular surgery, macular edema, retinal venous occlusion, subchoroidal neovascularization, retinal epithelial detachment, pterygum or foveal geographic atrophy of the retinal pigment epithelium.

First Claim

See full text

Other Claims data not available

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
OXEA GMBH46147 OBERHAUSEN

International Classification(s)

loading....
  • 2011 Application Filing Year
  • A61K Class
  • 10915 Applications Filed
  • 8360 Patents Issued To-Date
  • 76.60 % Issued To-Date
Click to zoom InYear of Issuance% of Matters IssuedCumulative IssuancesYearly Issuances201120122013201420152016201720182019202020212022202320240255075100

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Backenroth, Samuel I New York, US 7 7
Taraporewala, Irach B White Plains, US 8 13

Cited Art Landscape

Load Citation

Patent Citation Ranking

  • 3 Citation Count
  • A61K Class
  • 14.18 % this patent is cited more than
  • 12 Age
Citation count rangeNumber of patents cited in rangeNumber of patents cited in various citation count ranges93340159383591527830328862201 - 1011 - 2021 - 3031 - 4041 - 5051 - 6061 - 7071 - 8081 - 9091 - 100100 +025050075010001250150017502000225025002750300032503500375040004250

Forward Cite Landscape

Load Citation